Skip to main content
. 2018 Mar 6;2018:6202876. doi: 10.1155/2018/6202876

Figure 5.

Figure 5

The tumor-specific targeting of IR783-NBs-Affibody towards HER2 (+)/(−) breast cancer cells. (a, c)The targeting rate of NBs, NBs-Affibody, and IR783-NBs-Affibody for HER2 (+) breast cancer cells (BT-474) and HER2 (−) breast cancer cells (MDA-MB-231) via flow cytometry. (b, d) LSCM pictures of BT-474 and MDA-MB-231 cells coincubated with NBs, NBs-Affibody, and IR783-NBs-Affibody with a ×20 objective lens.